Zhang Hengwei, Yang Lei, Liu Zhangyi, Liu Chenxi, Teng Xuyong, Zhang Lei, Yin Bo, Liu Zhen
Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.
Department of General Surgery, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning 110001, P.R. China.
Oncol Lett. 2017 Sep;14(3):3734-3740. doi: 10.3892/ol.2017.6574. Epub 2017 Jul 15.
Previous studies have demonstrated that C-X-C chemokine receptor type 7 (CXCR7) regulates papillary thyroid carcinoma (PTC) growth and metastasis; however, the molecular mechanisms underlying this regulation remain unclear. In the present study, the protein expression profiles of the PTC cell line GLAG-66 and GLAG-66 cells stably transfected with CXCR7 cDNA were analyzed and compared using isobaric tag for relative and absolute quantification-coupled two-dimensional liquid chromatography-tandem mass spectrometry. In total, 2,983 proteins were quantified and 130 proteins were identified to be differentially expressed, of which 87 were significantly upregulated and 43 were significantly downregulated. Gene Ontology enrichment analysis revealed that the differentially expressed proteins were primarily enriched in a number of biological processes, including metabolism-related processes, cellular component organization, transport, cellular development process and the immune response. The differentially expressed proteins identified included fibronectin 1, basigin, periplakin and serpin family B member 5, all of which are associated with cellular junctions and cancer progression. In addition, transgelin-2 and AHNAK nucleoprotein 2 were identified as potential novel biomarkers for the prognosis and treatment of PTC.
先前的研究表明,C-X-C趋化因子受体7型(CXCR7)调节甲状腺乳头状癌(PTC)的生长和转移;然而,这种调节的分子机制仍不清楚。在本研究中,使用相对和绝对定量等压标签耦合二维液相色谱-串联质谱法分析并比较了PTC细胞系GLAG-66和稳定转染CXCR7 cDNA的GLAG-66细胞的蛋白质表达谱。总共定量了2983种蛋白质,鉴定出130种蛋白质差异表达,其中87种显著上调,43种显著下调。基因本体富集分析表明,差异表达的蛋白质主要富集在一些生物学过程中,包括代谢相关过程、细胞成分组织、运输、细胞发育过程和免疫反应。鉴定出的差异表达蛋白质包括纤连蛋白1、基底膜蛋白、周膜蛋白和丝氨酸蛋白酶抑制剂家族B成员5,所有这些都与细胞连接和癌症进展相关。此外,原肌球蛋白-2和AHNAK核蛋白2被鉴定为PTC预后和治疗的潜在新型生物标志物。